SCIENTIFIC LITERATURE · MED

Clinical Review Report: Levodopa/Carbidopa (Duodopa): (Abbvie Corporation): Indication: For the treatment of patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products, and, for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube required for administration

· 2018-09-01

PMID: 30958666

Research overview

This section identifies the original publication. Follow the source for its authors and journal.

Assess the question within the original study’s scope.

Check the source article for study design and sample details.

An editorially approved findings summary is not yet published for this record.

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.